Last updated: 23 September 2019 at 9:06pm EST

George F Tidmarsh Net Worth




The estimated Net Worth of George F Tidmarsh is at least $169 Thousand dollars as of 19 September 2019. George Tidmarsh owns over 151,291 units of Odonate Therapeutics Inc stock worth over $169,446 and over the last 14 years George sold ODT stock worth over $0.

George Tidmarsh ODT stock SEC Form 4 insiders trading

George has made over 12 trades of the Odonate Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently George exercised 151,291 units of ODT stock worth $169,446 on 19 September 2019.

The largest trade George's ever made was exercising 151,291 units of Odonate Therapeutics Inc stock on 19 September 2019 worth over $169,446. On average, George trades about 4,893 units every 47 days since 2010. As of 19 September 2019 George still owns at least 151,291 units of Odonate Therapeutics Inc stock.

You can see the complete history of George Tidmarsh stock trades at the bottom of the page.



What's George Tidmarsh's mailing address?

George's mailing address filed with the SEC is C/O ODONATE THERAPEUTICS, INC., 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO, CA, 92121.

Insiders trading at Odonate Therapeutics Inc

Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis, and Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.



What does Odonate Therapeutics Inc do?

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.



What does Odonate Therapeutics Inc's logo look like?

Odonate Therapeutics Inc logo

Complete history of George Tidmarsh stock trades at Anavex Life Sciences, La Jolla Pharmaceutical Co, Spectrum Pharmaceuticals, and Odonate Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Sep 2019 George F Tidmarsh
Director
Option 151,291 $27.48 $4,157,477
19 Sep 2019
151,291
7 Jan 2019 George F Tidmarsh
President and CEO
Buy 2,000 $5.85 $11,700
7 Jan 2019
1,283,326
2 Mar 2017 George F Tidmarsh
President and CEO
Buy 3,000 $34.17 $102,510
2 Mar 2017
1,354,086
1 Mar 2016 George F Tidmarsh
President and CEO
Buy 2,000 $16.57 $33,140
1 Mar 2016
1,425,086
12 May 2015 George F Tidmarsh
President and CEO
Buy 4,000 $18.37 $73,480
12 May 2015
1,423,086
11 Dec 2014 George F Tidmarsh
President and CEO
Buy 4,000 $11.38 $45,520
11 Dec 2014
1,421,086
26 Sep 2014 George F Tidmarsh
President and CEO
Buy 2,000 $9.35 $18,700
26 Sep 2014
1,417,086
18 Sep 2014 George F Tidmarsh
President and CEO
Buy 5,000 $9.18 $45,900
18 Sep 2014
1,415,086
23 Jul 2014 George F Tidmarsh
President and CEO
Buy 19,000 $10.50 $199,500
23 Jul 2014
1,410,086
21 May 2014 George F Tidmarsh
President and CEO
Buy 12,000 $7.37 $88,440
21 May 2014
20,000
11 Apr 2014 George F Tidmarsh
President and CEO
Buy 8,000 $9.53 $76,240
11 Apr 2014
4,000
7 Feb 2014 George F Tidmarsh
President and CEO
Buy 3,000 $7.25 $21,750
7 Feb 2014
1,391,086


Odonate Therapeutics Inc executives and stock owners

Odonate Therapeutics Inc executives and other stock owners filed with the SEC include: